Lupin— the largest manufacturer of anti-TB drugs in the world — has recorded one of the sharpest rise in sales in the domestic market over the last 12 months, according to the latest data available from research firm ORG-IMS.
Pharmaceutical major Lupin Ltd posted 25 per cent rise in net profit at Rs 140.10 crore during the first quarter of the current fiscal as compared to Rs 112 crore in the corresponding quarter of the previous year.
Galderma Laboratories, a joint venture dermatology company between Nestle and L'Oreal, and the New York University have sued Lupin Ltd for infringing the patent rights of one of its main drugs, Oracea.
Lupin Ltd, one of the top five drug companies in India, grew over 30 per cent yearly in the past four years and maintained 38 per cent growth in turnover and 49 per cent growth in profits in the first nine months of 2008-09. Kamal K Sharma, managing director, tells PB Jayakumar the company did it through strategic acquisitions, direct to market strategy in the US and careful selection of products.
The Rs 2,700 crore Lupin Ltd, is aggressively expanding its global footprint by acquiring companies, entering into alliances and enhancing its presence in select markets.
Pharma company Lupin today informed the Bombay Stock Exchange that the company has received US Food and Drug Administration (USFDA) approval for the company's abbreviated new drug application for Ramipril capsules, 1.25 mg, 2.5 mg, 5 mg and 10 mg.
Drug major Lupin Ltd has posted a net profit of Rs 95.8 crore for the quarter ended March 31, 2008, 32.1 per cent lower than the Rs 141.1 crore net profit posted in the corresponding previous year quarter.
Sun Pharmaceutical Industries and Lupin Ltd will soon add another generic drug each to their US product basket. The companies recieved approvals from the US drug regulator (USFDA) to market generic
The Rs 1300 crore antibiotic major Lupin Ltd has setup a panel of 16 doctors and 1 microbiologist to discuss the need for providing improved critical care in rural areas.
The Rs 1,200-crore pharma major Lupin Ltd is planning to acquire three to four major pharma brands in the US as part of its proposed inorganic growth plans there.
The Rs 1,200 crore Lupin Ltd has launched Ceftriaxone, the generic version of Rocephine, in the US market. Lupin had received the FDA approval for the generic product for the US market along with
Lupin Ltd has tied up with the US-based specialty pharma marketing company Henry Scheil to market formers ceftriaxone generic in the doctors clinic segment.
Content Guide
